Clinical Trial Update: Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML [Phase 1]

View source ↗

Summary

Phase 1 trial exploring axatilimab with decitabine and venetoclax for TP53-mutated acute myeloid leukemia; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Axatilimab (axatilimab)
• Decitabine (Decitabine)
• Venetoclax (venetoclax)

Snippet

Sponsor: Northside Hospital, Inc. | Conditions: Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Status: NOT_YET_RECRUITING